U.S. Industrials Stock News

NasdaqGS:HST
NasdaqGS:HSTHotel and Resort REITs

Host Hotels And Resorts HST Q4 FFO Strength Tests Bearish Earnings Decline Narrative

Host Hotels & Resorts (HST) has wrapped up FY 2025 with fourth quarter total revenue of US$1.6 billion and basic EPS of US$0.20, alongside funds from operations of US$340 million that remain the key gauge for this REIT. Over recent quarters, the company has seen revenue move from US$1.42 billion in Q4 2024 to US$1.60 billion in Q4 2025, while basic EPS shifted from US$0.15 to US$0.20. This gives investors a clearer view of how the top line and per share results are tracking into the latest...
NasdaqGM:AAOI
NasdaqGM:AAOICommunications

Applied Optoelectronics Ramps Up For AI Demand As Dilution Questions Grow

Applied Optoelectronics (NasdaqGM:AAOI) reports record fourth quarter and full year revenue driven by demand in data center and CATV segments. The company highlights rapid growth in orders for next generation 800G transceivers linked to hyperscale and AI data center investments. AAOI plans a major manufacturing expansion, including a new facility in Texas and a plan to triple laser manufacturing capacity. The company launches a US$250 million at the market stock offering to support growth...
NasdaqGS:TWST
NasdaqGS:TWSTBiotechs

Is Twist Bioscience (TWST) Using Invenra Deal To Quietly Redefine Its Biologics Platform Strategy?

In February 2026, Twist Bioscience Corporation announced it had entered a licensing agreement with Invenra Inc., becoming co-exclusive provider of Invenra’s B-Body bispecific antibody platform and extending its antibody discovery services, in exchange for US$5,000,000 in cash, US$15,000,000 in common stock, and an additional US$13,800,000 stock-funded preferred stake of about 6% in Invenra. By securing rights to Invenra’s bispecific antibody technology and all associated discovery and...
NYSE:BHC
NYSE:BHCPharmaceuticals

Is Bausch Health (BHC) Pricing Reflect Its Sharp Multi‑Year Share Price Declines?

If you are looking at Bausch Health Companies and wondering whether the current share price reflects its underlying value, you are not alone. The stock last closed at US$6.04, with returns of 1.9% over the past week and 5.6% over the past month, against year to date and 1 year returns of 16.2% and 21.0% declines, and a 34.7% and 81.1% decline over 3 and 5 years respectively. These moves have kept valuation in focus for many investors, especially as headlines continue to frame Bausch Health...
NYSE:TFX
NYSE:TFXMedical Equipment

Teleflex (TFX) Discontinued Losses Challenge Bullish Earnings Growth Narrative

Teleflex (TFX) has just posted its FY 2025 fourth quarter numbers, with revenue of US$569 million and a basic EPS loss of US$0.08, while trailing twelve month revenue sits at US$2.0 billion and EPS at US$1.31. Over recent quarters, revenue has ranged from US$569 million to US$913 million, with quarterly basic EPS swinging between a loss of US$9.24 and a profit of US$2.77. This underscores how headline earnings have been heavily affected by discontinued operations and one off items. With...
NYSE:WAB
NYSE:WABMachinery

Is It Too Late To Consider Wabtec (WAB) After Its Strong Multi‑Year Rally?

If you are wondering whether Westinghouse Air Brake Technologies at around US$263.41 is priced for perfection or still offers value, this article is designed to help you frame that question clearly. The stock has recent returns of 0.6% over 7 days, 13.7% over 30 days, 21.8% year to date, 46.1% over 1 year and 273.9% over 5 years, which naturally raises questions about growth potential and how risk is being priced in now. Recent news coverage around Westinghouse Air Brake Technologies has...
NYSE:TAL
NYSE:TALConsumer Services

Is TAL Education Group (TAL) Mispriced After Years Of Share Price Weakness?

If you are wondering whether TAL Education Group's share price still reflects its true value, you are not alone, especially given how different its past performance looks over various time frames. The stock last closed at US$10.89, with returns of 0.2% decline over 7 days, 2.3% over 30 days, a 5.2% decline year to date, a 17.9% decline over 1 year and 37.8% over 3 years, compared with a much larger 85.5% decline over 5 years. These mixed returns sit against a backdrop of ongoing regulatory...
NYSE:FLS
NYSE:FLSMachinery

What Flowserve (FLS)'s Dividend Hike and Analyst Upgrades Mean For Shareholders

Earlier this month, Flowserve Corporation’s Board of Directors approved a quarterly cash dividend of US$0.22 per share, a 5% increase on the prior payout, payable on April 10, 2026 to shareholders of record as of March 27, 2026. This higher dividend, alongside recent upward analyst earnings revisions and recognition for strong momentum characteristics, highlights growing confidence in Flowserve’s operational and market positioning. Next, we’ll examine how the recent dividend increase and...
NYSE:MKC
NYSE:MKCFood

Is McCormick’s (MKC) Reformulation Push Quietly Reshaping Its Long‑Term Competitive Moat?

Earlier this month, McCormick & Company filed an omnibus shelf registration covering common stock, non-voting common stock, and debt securities, while its CEO reported a surge in customer requests to reformulate products by removing artificial ingredients, cutting salt, and adding new flavor concepts. By moving earlier into customers’ product development cycles and focusing reformulation on emerging consumer preferences, McCormick is positioning its flavor expertise as a core ingredient in...
NYSE:HLF
NYSE:HLFPersonal Products

Herbalife Debt Refinance Puts Financial Flexibility And Growth Narrative In Focus

Herbalife (NYSE:HLF) has launched a major refinancing of its senior secured debt, targeting a large portion of its existing obligations. The company is pairing this move with an update on product driven performance, highlighting strong momentum in markets such as India. Management is also emphasizing continued investment in its distributor network alongside ongoing product development. Herbalife comes into this refinancing with its shares at $19.28 and a mixed return profile. The stock is...
NasdaqGM:PAYO
NasdaqGM:PAYODiversified Financial

Payoneer Global PAYO Margin Drop To 7% Tests Bullish Earnings Growth Narrative

Payoneer Global FY 2025 Earnings Snapshot Payoneer Global (PAYO) has capped FY 2025 with fourth quarter total revenue of US$274.7 million and basic EPS of US$0.05, while trailing twelve month revenue sits at about US$1.1 billion alongside basic EPS of roughly US$0.20. Over recent periods, the company has seen quarterly revenue move from US$261.7 million in Q4 2024 to US$274.7 million in Q4 2025, with basic EPS shifting between US$0.05 and US$0.06 over the FY 2025 quarters. With trailing net...
NYSE:IONQ
NYSE:IONQTech

IonQ (IONQ) Posts US$61.9 Million Q4 Revenue Challenging Profitability Skepticism

IonQ (IONQ) has just wrapped up FY 2025 with fourth quarter revenue of about US$61.9 million and basic EPS of US$2.18, alongside trailing 12 month revenue of roughly US$130.0 million and basic EPS of US$1.82. Over the past six reported quarters, the company has seen quarterly revenue range from US$7.6 million in early 2025 to US$39.9 million in the third quarter and then to US$61.9 million in the fourth quarter, while basic EPS has moved from a loss of US$0.93 in late 2024 to a loss of...
NasdaqGM:LNTH
NasdaqGM:LNTHMedical Equipment

Lantheus Holdings (LNTH) Net Margin Decline Tests Bullish Earnings Growth Narrative

Lantheus Holdings (LNTH) has just closed out FY 2025 with Q4 revenue of US$406.8 million and basic EPS of US$0.82, alongside trailing twelve month revenue of about US$1.5 billion and basic EPS of US$3.46 that frame the latest quarter in a broader earnings context. Over the past few quarters, the company has seen revenue move from US$372.8 million in Q1 2025 to US$406.8 million in Q4 2025, while quarterly basic EPS shifted from US$1.06 to US$0.82 and trailing net profit margin sits at 15.2%...
NasdaqGM:PTGX
NasdaqGM:PTGXBiotechs

Protagonist Therapeutics (PTGX) Quarterly Loss Deepens To US$44.4m And Tests Bullish Profitability Narrative

Protagonist Therapeutics (PTGX) closed FY 2025 with Q4 revenue of US$7.4 million and a basic EPS loss of US$0.69, alongside a Q4 net loss of US$44.4 million. On a trailing twelve month basis, revenue was US$46.0 million with a basic EPS loss of US$2.05 and a net loss of US$130.1 million. The company has reported quarterly revenue ranging from US$28.3 million in Q1 2025 down to US$4.7 million in Q3 2025. Basic EPS moved from a loss of US$0.19 in Q1 to a loss of US$0.62 in Q3 before reaching a...
NYSE:RHI
NYSE:RHIProfessional Services

Can Robert Half’s (RHI) New Marketing Chief Reframe Its Brand Edge In Global Staffing?

On February 17, 2026, Robert Half promoted long-time marketing leader Linda Christensen to senior vice president of global marketing, giving her responsibility for global brand positioning, digital modernization and data-driven marketing capabilities. The appointment signals a push to more tightly align Robert Half's marketing engine with its operating model and long-term growth plans amid a competitive global staffing landscape. We’ll examine how Christensen’s expanded remit over digital...
NasdaqGS:OPRA
NasdaqGS:OPRASoftware

Opera Links US$300m Buyback To AI Browser Growth Story

Opera Limited (NasdaqGS:OPRA) announced a share repurchase program of up to US$300 million, funded from operational cash flow and its balance sheet. The buyback comes alongside new AI integrated browser features that aim to deepen the role of AI in Opera's core products. The company highlighted that this capital return plan and product rollout are taking place while it manages ongoing geopolitical and market related risks. Opera operates a web browser and related internet services business,...
NYSE:CWH
NYSE:CWHSpecialty Retail

Camping World Holdings (CWH) Is Down 28.2% After Halting Dividend To Focus On Debt Reduction

In February 2026, Camping World Holdings reported fourth-quarter and full-year 2025 results showing quarterly revenue of US$1,173.56 million and a widening net loss of US$67.3 million, alongside a full-year net loss of US$89.8 million despite higher annual revenue of US$6,369.15 million. At the same time, the board paused Camping World’s regular quarterly cash dividend to prioritize reducing net debt leverage amid tax law changes and weaker profitability, marking a significant shift in how...
NasdaqGS:EZPW
NasdaqGS:EZPWConsumer Finance

Cramer Spotlight and Gold Activity Might Change The Case For Investing In EZCORP (EZPW)

Recently, Jim Cramer praised EZCORP, Inc. (NASDAQ: EZPW) on his show as a well-run pawn and credit business, while EZCORP’s chief revenue officer highlighted strong customer interest in selling gold amid near-record prices. Taken together, this favorable media attention and management commentary on gold-driven activity underscore how closely EZCORP’s pawn operations are linked to movements in precious metals markets. We’ll now explore how upbeat commentary on EZCORP’s operations and...
NYSE:JOBY
NYSE:JOBYAirlines

Joby Aviation (JOBY) Quarterly Loss Narrows To US$121.5 Million Challenging Bearish Narratives

Joby Aviation (JOBY) has just wrapped up FY 2025 with Q4 revenue of US$30.8 million and a basic EPS loss of US$0.14, alongside trailing twelve month revenue of US$53.4 million and a TTM basic EPS loss of US$1.13. Over recent quarters, the company has moved from effectively zero revenue in early 2025 to US$22.6 million in Q3 and US$30.8 million in Q4. Quarterly basic EPS losses ranged between US$0.11 and US$0.48. This sets up a story where top line traction is building against a backdrop of...
NYSE:CUBE
NYSE:CUBESpecialized REITs

Will Rising Revenue But Softer Earnings and Flat 2026 Outlook Change CubeSmart's (CUBE) Narrative?

CubeSmart recently reported fourth-quarter and full-year 2025 results showing higher revenue, as sales rose to US$240.93 million for the quarter and US$956.65 million for the year, but net income and earnings per share declined compared with 2024. Alongside affirming a US$0.53 quarterly dividend for April 2026, management issued 2026 guidance that points to flat to slightly negative same-store revenue and net operating income growth, highlighting a more cautious near-term outlook for the...
NasdaqGS:FFIN
NasdaqGS:FFINBanks

Is First Financial Bankshares (FFIN) Price Justified After Recent Rebound And Sector Concerns

If you are wondering whether First Financial Bankshares is reasonably priced or you might be overpaying at US$33.45, you are asking the right question before making any decisions. The share price has moved 1.1% over the last week, 5.1% over the past month, and 11.4% year to date, while the 1 year return sits at an 8.2% decline and the 3 and 5 year returns are 0.5% and 18.0% declines respectively. Recent coverage has focused on broad sector trends and regional bank conditions, which helps...
NasdaqGM:INOD
NasdaqGM:INODProfessional Services

Is Innodata (INOD) Pricing AI Hopes Too High After Recent Share Price Swings

This article is designed to help you assess whether Innodata's share price aligns with its underlying worth, or if sentiment has run ahead of fundamentals. Innodata last closed at US$47.58, with a 4.3% return over the past week, an 18.9% decline over the past month, a 10.2% decline year to date, a 9.6% decline over 1 year and a very large 3 year and 5 year return that is more than 7x. Recent headlines around Innodata have focused on its role in data engineering and AI related services,...
NasdaqGM:CRMD
NasdaqGM:CRMDPharmaceuticals

Is CorMedix (CRMD) Pricing Reflect Recent Share Weakness Or Future Growth Potential

If you are wondering whether CorMedix stock is priced attractively or already baking in a lot of optimism, you are in the right place to unpack what the current share price might be implying. CorMedix recently closed at US$7.35, with returns of 3.8% over the past 7 days, a 5.2% decline over 30 days, a 39.6% decline year to date, and a 28.3% decline over 1 year, set against a 73.8% return over 3 years and 3.7% over 5 years. Recent coverage of CorMedix has focused on its position within the...
NasdaqGS:HCSG
NasdaqGS:HCSGCommercial Services

Assessing Healthcare Services Group (HCSG) Valuation After Strong Recent Share Price Momentum

Context for Healthcare Services Group With no single headline event driving attention today, Healthcare Services Group (HCSG) is on many investors’ radar because of its recent share performance and current valuation signals in the commercial services space. See our latest analysis for Healthcare Services Group. At a share price of $21.76, Healthcare Services Group has seen firm momentum build recently, with a 30 day share price return of 16.74% and a 1 year total shareholder return of 106.26%...